1. Home
  2. DFIN vs TBPH Comparison

DFIN vs TBPH Comparison

Compare DFIN & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Donnelley Financial Solutions Inc.

DFIN

Donnelley Financial Solutions Inc.

HOLD

Current Price

$46.93

Market Cap

1.2B

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$15.16

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFIN
TBPH
Founded
1983
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
DFIN
TBPH
Price
$46.93
$15.16
Analyst Decision
Strong Buy
Buy
Analyst Count
2
6
Target Price
$61.50
$17.80
AVG Volume (30 Days)
227.2K
846.4K
Earning Date
04-29-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
279.13
EPS
1.15
2.06
Revenue
$963,000,000.00
$15,386,000.00
Revenue This Year
$4.98
$9.51
Revenue Next Year
$3.87
N/A
P/E Ratio
$40.78
$7.42
Revenue Growth
N/A
N/A
52 Week Low
$37.07
$7.90
52 Week High
$66.25
$21.03

Technical Indicators

Market Signals
Indicator
DFIN
TBPH
Relative Strength Index (RSI) 45.85 46.28
Support Level $44.46 $13.41
Resistance Level $48.65 $19.04
Average True Range (ATR) 1.74 0.41
MACD -0.21 0.31
Stochastic Oscillator 33.56 80.00

Price Performance

Historical Comparison
DFIN
TBPH

About DFIN Donnelley Financial Solutions Inc.

Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: